Evidence map›Paper›PMID 42131601›Full record

ArticleFrontiers in medicine2026

Sequential nasal and mammary myeloid sarcoma with a 6-year latency: a case report and literature review.

Jiaxin Yu, Chuanlin Hou, Feng Xu

Abstract readCase Reports
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jiaxin YuSchool of Medicine, Shaoxing University, Shaoxing, Zhejiang, China.
Chuanlin HouDepartment of Pathology, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.
Feng XuDepartment of General Surgery, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid sarcoma (MS) is a rare extramedullary manifestation of acute myeloid leukemia. While MS can involve various organs, isolated involvement of the nasal cavity or breast is uncommon, and the sequential involvement of both sites in a single patient is extremely rare. We present the case of a 68-year-old female who developed an MS relapse in the right breast 6 years after being treated for primary MS of the right nasal cavity. In 2018, she presented with a right nasal mass, initially suspected clinically to be a polyp. Histopathological and immunohistochemical (IHC) analyses confirmed MS. She achieved complete remission following localized radiotherapy and cytarabine-based systemic chemotherapy. After a six-year disease-free interval, she presented in 2025 with a painful right breast nodule. Initial imaging indicated a primary breast malignancy (BI-RADS 4B). However, postoperative IHC analysis, demonstrating myeloperoxidase (MPO) positivity, confirmed an extramedullary relapse of MS. The patient was subsequently treated with further chemotherapy and hypofractionated radiotherapy. This case highlights that extramedullary MS can perfectly mimic primary solid tumors both clinically and morphologically. It emphasizes the critical role of a comprehensive immunohistochemical panel, particularly the inclusion of myeloid-specific markers, in differentiating MS from poorly differentiated carcinomas. Such pathological vigilance is indispensable for avoiding catastrophic diagnostic pitfalls and preventing inappropriate surgical interventions in patients presenting with atypical extramedullary masses.

Indexed as

breast neoplasmsextramedullary relapsemyeloid sarcomanasal cavitytumor dormancy

Identifiers

PMID42131601
PMCPMC13160841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.